Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Saroglitazar and vitamin E vs. lifestyle interventions in metabolic dysfunction associated steatotic liver disease: A 3-arm randomised study.

  • 2026-05-16
  • The Indian journal of medical research 163
    • Anurag Kumar Tiwari
    • Gurvachan Singh
    • Vinod Kumar
    • Dawesh Prakash Yadav
    • Sunit Kumar Shukla
    • Virendra Singh
    • Gaurav Mishra
    • Narendra Kumar Tiwary
    • Anand Anunay
    • Divyanshi Singh
    • Deepika Chaturvedi

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 136
Population
150 non-diabetic patients aged 19-55 yr
Methods
Patients were recruited to receive saroglitazar and vitamin E along with lifestyle interventions and lifestyle interventions alone (n=50 in each arm) for 24 weeks
Blinding
Open-label
Duration
24 weeks
Funding
Unclear
  • Large Human Trial
Background and objectives Lifestyle interventions are a vital component for the management of metabolic dysfunction-associated steatotic liver disease (MASLD). In the present study, we investigated the differential effect of saroglitazar or vitamin E vs. lifestyle interventions only. Methods A total 150 non-diabetic patients aged 19-55 yr were recruited to receive saroglitazar and vitamin E along with lifestyle interventions and lifestyle interventions alone (n=50 in each arm, A, B and C, respectively) for 24 weeks. Liver stiffness measurements and NAFLD fibrosis score were the primary outcomes. The study was registered under Trial registration (CTRI/2022/05/042462). Results Per-protocol analysis was performed in 136 patients (n=46, 47, and 43 in arms A, B and C, respectively). The changes from baseline were not-significant for NAFLD fibrosis score [0.05±0.52, 0.06±0.64 and -0.12±1.0, 95% confidence interval (CI), P =0.41] and liver stiffness measurement [-1.25 (-2.6, -0.2), -1.4 (-3.7, 0.4,) and -0.7 (-1.8, -0.2), P =0.22] in either arm. Changes in secondary outcomes were also not-significant except triglyceride [-13.95 (-61, -18), -4.3 (-28.8, 49) and -13 (-127, 3) P=0.035]. A considerable proportion of patients had at least '2 Kpa reduction' in liver stiffness measurement in arm A (39%) compared to C (19%). Interpretation and conclusions Saroglitazar or vitamin E are similar to lifestyle interventions in improving different non-invasive parameters in MASLD at 24 weeks of intervention.

Research Insights

  • Vitamin E→Reduced Liver Stiffness

    liver stiffness measurement [-1.25 (-2.6, -0.2), -1.4 (-3.7, 0.4,) and -0.7 (-1.8, -0.2), P =0.22]

    Effect
    Neutral
    Effect size
    Small
    Dose
    not specified in abstract
  • Vitamin E→Reduced NAFLD Fibrosis Score

    The changes from baseline were not-significant for NAFLD fibrosis score [0.05±0.52, 0.06±0.64 and -0.12±1.0, 95% confidence interval (CI), P =0.41]

    Effect
    Neutral
    Effect size
    Small
    Dose
    not specified in abstract
  • Vitamin E→Reduced Triglyceride Levels

    Changes in secondary outcomes were also not-significant except triglyceride [-13.95 (-61, -18), -4.3 (-28.8, 49) and -13 (-127, 3) P=0.035]

    Effect
    Neutral
    Effect size
    Small
    Dose
    not specified in abstract
Back to top